Aurobindo Pharma's Acrotech Launches Adquey Ointment, Entering US Dermatology Market

Business Standard · business

Aurobindo Pharma's subsidiary Acrotech Biopharma has launched Adquey ointment in the United States, marking its entry into the American dermatology market. This non-steroidal topical treatment is for mild-to-moderate atopic dermatitis in adults and children aged two and above. Originally discovered by Otsuka Pharmaceutical, the drug was licensed to Acrotech for US commercialisation. The company has established a dedicated dermatology business unit to support this launch and market expansion. Adquey will compete in a US market valued at approximately $1.3 billion.